Article
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Cancer discovery - 1 Dec 2016
Hong David S, Morris Van K, El Osta Badi, Sorokin Alexey V, Janku Filip, Fu Siqing, Overman Michael J, Piha-Paul Sarina, Subbiah Vivek, Kee Bryan, Tsimberidou Apostolia M, Fogelman David, Bellido Jorge, Shureiqi Imad, Huang Helen, Atkins Johnique, Tarcic Gabi, Sommer Nicolas, Lanman Richard, Meric-Bernstam Funda, Kopetz Scott
Abstract excerpt
In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic cytotoxicity for BRAFV600E metastatic colorectal cancer, further augmented by irinotecan. The safety and efficacy of vemurafenib, irinotecan, and cetuximab in BRAF-mutated malignancies are not defined. In this 3+3 phase I study, patients with BRAFV600E-advanced solid cancers received cetuximab and irinotecan with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.